Outsourcing in Clinical Trials Nordics 201417-18 September 2014, Copenhagen, Denmark
With healthcare innovation and growth being considered a top priority for the Nordic region, clinical trials are regarded as a key aspect of delivery innovation, with governments incentivising and rewarding such efforts. One of the key considerations for the Nordics is the need for collaboration. Furthermore, with the increased rewards for innovation, the industry is looking to increase R&D activity, which in turn means there will be considerable development within clinical trials. Against this backdrop, OCT Nordics will allow companies from within this Nordic-specific hub to come together and discuss proven strategies to improve and create partnerships within clinical trials and medical devices.
Alongside the biopharmaceutical outsourcing sessions, we will also include unique medical device-specific sessions in a separate stream covering: medical device outsourcing, patient recruitment and new regulations (e.g. MDD). This year’s event will have more of an operational focus and bring together senior industry representatives to discuss the latest challenges within clinical outsourcing and medical device-related challenges such as: improved vendor communication strategies, vendor sourcing/selection, budgeting and contracting, oversight and management, patient recruitment, risk-based monitoring and feasibility plans.
Outsourcing in Clinical Trials Nordics 2014 promises to be a highly engaging meeting and will present a unique platform for discussion alongside thought-sharing on innovative strategies within outsourcing models in this ever-growing region.
Whether you are a senior professional in a global pharmaceutical company or a smaller company looking to expand, access to insight and knowledge about the latest pharmaceutical trends is vital.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
Primary delegates for this event are those with responsibility for clinical outsourcing in biotech and pharma companies within the Nordic region.
We are always happy to see photos taken at our events! If you have any you would like to submit, please email firstname.lastname@example.org The Arena Team
Testimonials from other events in our Outsourcing in Clinical Trials Series
Outsourcing in Clinical Trials Nordics boasts a fantastic exhibition of clinical service providers and industry specialists. Our exhibition area is already filling up due to the fantastic launch event which took place this year. If you have a service or solution you would like to promote at this event, please use the details below to make contact with our commercial team.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have reported results from an investigational Phase III trial of sorafenib (Nexavar) tablets plus capecitabine in patients with advanced breast cancer.
Cardioxyl Pharmaceuticals has reported positive results from a Phase I clinical trial showing that CXL-1427, a new potential treatment for acute decompensated heart failure (ADHF).
US-based biopharmaceutical firm Esperion Therapeutics has dosed the first patient in its Phase II clinical trial of ETC-1002 to treat patients with hypercholesterolemia and hypertension, ETC-1002-014.
US-based biopharmaceutical firm Reata Pharmaceuticals has enrolled the first patient in a Phase II dose-ranging trial of RTA 408 Lotion in breast cancer patients at risk for radiation dermatitis.
LFB Biotechnologies’ subsidiary rEVO Biologics has enrolled the first patient in its Phase III clinical trial of ATryn to treat preeclampsia.
US-based pharmaceutical firm Merck has enrolled the first patient in a global Phase III clinical trial of letermovir (MK-8228), an investigational antiviral agent, for prevention of cytomegalovirus (CMV) infection in high-risk bone marrow transplant …